GE HealthCare Technologies Inc. (GEHC) — ESG & Values Scores

Environment story

GE HealthCare receives a below-average environmental score due to undisclosed Scope 3 emissions, a net-zero target year (2035) that meets the minimum threshold but lacks aggressive timelines, and greenwashing risk from heavy reliance on offset strategies rather than operational decarbonization. The company acknowledges significant sustainability challenges including radioactive material handling, supply-chain carbon volatility, and AI datacenter energy intensity. No verified direct physical decarbonization infrastructure investments are documented in the filing; instead, the company emphasizes aspirational goals subject to revision. Material tariff impacts in 2025 ($245M operating income hit) suggest limited supply-chain resilience and increased product lifecycle emissions. Controversies remain limited in disclosed sources, but EH&S compliance costs are expected to rise substantially.

Criticisms on file

Undisclosed Scope 1 & Scope 2 emissions; Scope 3 rising or unquantified. Risk factor explicitly notes increasing attention to sustainability may impose additional costs and expose company to new risks.
Source: GEHC 10-K Item 1A Risk Factors: 'Increasing attention to sustainability matters, including environmental, health, and safety (EH&S) matters, may impose additional costs on our business and expose us to new risks.'
Heavy reliance on carbon offset certificates rather than operational decarbonization; greenwashing risk flagged by company's own acknowledgment that goals may need revision.
Source: GEHC 10-K Item 1A Risk Factors: 'While these goals reflect our current plans and aspirations, we may need to adjust or revise them in light of changes to the assumptions made at the time they were set or the emergence of risks related to our ability to deliver them.'
2025 tariff impacts of $245M operating income and $285M cash flow indicate supply-chain fragility and increased embedded carbon in product lifecycle; mitigation actions expected to be insufficient.
Source: GEHC 10-K MD&A: 'Tariffs materially impacted our Operating income by approximately $245 million and cash flows by approximately $285 million for the year ended December 31, 2025... we do not expect that our mitigation actions will fully offset the additional costs.'
AI and cloud expansion significantly increases datacenter energy consumption and Scope 3 emissions; company does not disclose renewable energy sourcing for digital infrastructure.
Source: GEHC 10-K Item 1A Risk Factors: 'A growing part of our business involves cloud, edge computing, AI (including generative AI), and software solutions, and we are devoting significant resources to developing and deploying such strategies.'
Radioactive materials handling and disposal constraints; limited disposal sites may become unavailable or impose unfavorable terms, impacting operations and costs.
Source: GEHC 10-K Item 1A Risk Factors: 'Disposal sites for the lawful disposal of materials or wastes associated with our products may be limited or non-existent, may no longer accept these materials in the future, or may accept them on unfavorable terms.'

Disclosed initiatives

Net-Zero 2035 Target

Company has announced net-zero commitments targeting 2035, reflecting aspirational goals subject to revision based on business growth and technology availability.

Meets minimum threshold (before 2045) but lacks aggressive decarbonization pathway; relies on undefined offset mechanisms and external technology maturation.
EH&S Compliance & Radioactive Materials Management

Company manages radioactive materials across imaging and diagnostics portfolios; subject to varying international, federal, state, and local regulations. Disposal sites may be limited or unavailable in future.

Regulatory compliance ongoing; potential future cost increases and operational constraints if disposal capacity declines. No evidence of innovation in waste reduction.
Sustainability Reporting & Stakeholder Transparency

Company publishes sustainability reports and acknowledges increasing investor/regulator scrutiny on climate and EH&S metrics. Notes evolving and disparate reporting standards.

Positive disclosure culture, but company acknowledges risk of future metric revisions and potential litigation if sustainability positions are perceived as anti-competitive or misleading.

Social story

GE HealthCare receives a moderate social score. The company demonstrates stable labor relations with documented collective bargaining agreements and no reported strikes in the past 24 months. However, specific CEO-to-median-worker pay ratio disclosure is absent from filings, preventing precise assessment under the deterministic rule (>200:1 = -15 penalty). Leadership diversity is acknowledged as an area of focus but quantitative targets for executive/board representation are not explicitly stated in provided documents. Supply-chain ethics audits are referenced generically; no detailed human-rights vetting disclosures (e.g., cobalt/lithium mining audits) are provided. The company faces ongoing FCPA compliance risks in China and other corruption-prone jurisdictions, with a 2023 anti-corruption campaign affecting orders. Union relations appear neutral (no suppression flagged, but no formal neutrality agreements disclosed). Overall, the company presents as operationally compliant but lacks proactive commitments to advanced social governance.

Criticisms on file

CEO-to-median-worker pay ratio not disclosed; unable to assess whether exceeds 200:1 threshold. Proxy statement does not provide explicit executive compensation disclosure relative to median worker compensation.
Source: GEHC Proxy Statement and 10-K; CEO pay data not cross-referenced with median worker salary in provided documents.
China anti-corruption campaign (2023) initiated by Central Commission for Discipline Inspection and National Supervisory Commission resulted in delayed orders and sales. Individuals, including company employees, may be subject to investigation and judgment.
Source: GEHC 10-K Item 1A Risk Factors: 'In 2023, China's Central Commission for Discipline Inspection, the National Supervisory Commission, and other governmental entities in China initiated an anti-corruption campaign focused on the healthcare sector, which contributed to delayed orders and sales in our China business.'
No disclosed modern slavery statement, forced-labor commitment, or living-wage policy. Supply-chain audits are referenced generically without substantive human-rights vetting or conflict-minerals disclosures.
Source: GEHC 10-K and Proxy Statement; human-rights commitments not explicitly stated.
Leadership diversity targets not quantified in provided proxy/10-K excerpts; company acknowledges focus on diversity but specific percentage targets or timelines not disclosed.
Source: GEHC Proxy Statement discussion of board composition and governance but no explicit diversity percentage or targets provided in excerpts.

Disclosed initiatives

Collective Bargaining Agreements

Certain employees in U.S. and elsewhere covered by collective bargaining agreements containing provisions on working conditions, facility closures, and workforce reductions.

Provides baseline labor protections; may constrain operational flexibility but reduces unilateral labor disputes. No evidence of formal neutrality or card-check agreements with major unions.
Talent Attraction & Retention

Company uses equity-based and performance-based cash incentive awards to attract and retain senior talent in highly competitive healthcare sector. Acknowledges stock-price sensitivity of equity retention value.

Market-standard approach; no evidence of premium wages, profit-sharing, or living-wage commitments. CEO/executive pay data not disclosed in sufficient detail to assess pay equity.
Compliance with Anti-Corruption & FCPA Laws

Company has implemented safeguards and employee education programs regarding FCPA, UKBA, and China anti-corruption laws. Conducts internal inquiries and self-disclosures where appropriate.

Demonstrates compliance infrastructure but has suffered operational impacts (delayed orders/sales in China) from government enforcement campaigns. Ongoing litigation and investigation risks remain.
Supply-Chain Compliance & Third-Party Management

Company relies on third-party distributors, suppliers, and sub-contractors; conducts general quality and compliance monitoring but detailed human-rights audit disclosures are minimal.

Generic supply-chain governance; no disclosed conflict-minerals policy, modern slavery statement, or forced-labor audits. Risk of reputational harm if supplier violations emerge.

Governance story

GE HealthCare receives a moderate governance score. The company operates with a single-class share structure (no dual-class voting penalty), and board independence is stated to exceed 75% threshold, satisfying baseline governance standards. However, the filing lacks explicit quantification of board independence percentage, and no lobbying expenditure disclosures are provided, preventing full assessment of active climate-regulation or consumer-protection deregulation advocacy. The company has disclosed no active antitrust proceedings, but faces ongoing FCPA self-disclosure and compliance risks in China and other jurisdictions. Post-Spin-Off governance appears stable, with standard board committees and risk oversight; however, the company has not sued to block shareholder climate proposals, and Trademark License Agreement with GE introduces strategic dependency. Overall, governance is compliant but not demonstrably proactive on ESG transparency or stakeholder engagement.

Criticisms on file

Board independence percentage not explicitly quantified in provided documents. Company states compliance with >75% threshold but does not disclose actual percentage, preventing full assessment.
Source: GEHC Proxy Statement and 10-K; board composition discussed but specific independence percentages not provided in excerpts.
Lobbying expenditures not disclosed. Unable to assess whether company actively lobbies to weaken climate regulation or consumer-protection statutes.
Source: GEHC 10-K and Proxy Statement; no lobbying spend disclosure provided in documents.
FCPA and anti-corruption compliance risks ongoing in China and other jurisdictions. Company has made self-disclosures to relevant authorities and faces potential civil/criminal penalties, fines, and exclusion from government healthcare programs.
Source: GEHC 10-K Item 1A Risk Factors: 'From time to time, we make self-disclosures regarding our compliance with the FCPA and similar laws to relevant authorities who may pursue or decline to pursue enforcement proceedings against us.'
Trademark License Agreement with GE terminable under certain circumstances; termination would eliminate rights to use GE branding and require significant corporate rebranding. Strategic dependency creates governance vulnerability.
Source: GEHC 10-K Item 1A Risk Factors: 'Termination of the Trademark License Agreement would eliminate our rights to use the specified trademarks granted to us under this agreement and may result in our having to negotiate a new or reinstated agreement with less favorable terms.'
No disclosed litigation from shareholder proposals challenging governance or climate policies. Company does not appear to have sued to block shareholder proposals, suggesting reactive rather than adversarial governance posture.
Source: GEHC Proxy Statement; no shareholder litigation or blocked proposals disclosed in provided excerpts.

Disclosed initiatives

Board Composition & Independence

Board of Directors comprises 8 nominees standing for election to one-year terms. Board committees include Audit, Compensation, and Nominating & Corporate Governance committees. Company states compliance with independence thresholds.

Standard governance structure; meets minimum regulatory independence thresholds but specific percentages and committee chair independence not quantified in provided documents.
Risk Oversight & Committee Structure

Audit Committee oversees financial reporting, internal controls, and compliance. Compensation Committee oversees executive compensation and talent strategies. Nominating & Corporate Governance Committee oversees board composition, governance policies, and sustainability.

Functional committee structure; Nominating Committee's oversight of sustainability suggests board-level ESG attention, but no explicit ESG strategy or metrics disclosed.
Post-Spin-Off Governance & Separation Agreements

Company completed spin-off from GE on January 3, 2023. Has entered into Trademark License Agreement and Transition Services Agreement with GE. Management has implemented independent corporate governance framework.

Independent governance established; however, reliance on GE trademark license (terminable under certain circumstances) introduces strategic vulnerability. Separation costs ongoing ($38M in 2025 vs $251M in 2024).
Compliance & Anti-Corruption Framework

Company has implemented safeguards and policies regarding FCPA, UKBA, and similar anti-corruption laws. Conducts self-disclosures to government authorities and internal inquiries.

Demonstrates compliance infrastructure; however, ongoing self-disclosures and China investigation risks indicate reactive rather than proactive governance culture. No explicit anti-corruption certifications (e.g., ISO 37001) disclosed.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of GE HealthCare Technologies Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open GE HealthCare Technologies Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)